Who
David E. Cohen
Director
Company insider
Files Form 4 as: Director, Evommune; Director, Timber Pharmaceuticals; Director, Kadmon Holdings; Director, Dermira; Director, Connetics.
In numbers
- Trades disclosed
- 55
- Buys
- 0
- Sells
- 9
- Bought
- $0
- Sold
- $372K
- Companies
- 5
- Companies where not an officer
- 5
- First trade
- 22 May 2006
- Last trade
- 2 Jun 2026
- Last filed
- 3 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 2 Jun 2026filed 3 Jun 2026 | EVMN EvommuneBiotechnology | SEC FORM 4 Sold | $110K5,456 at $20.21 | filing |
| 2 Jun 2026filed 3 Jun 2026 | EVMN EvommuneBiotechnology | SEC FORM 4 Sold | $13K600 at $21.38 | filing |
| 2 Jun 2026filed 3 Jun 2026 | EVMN Evommuneoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,673 at $0.00 | filing |
| 2 Jun 2026filed 3 Jun 2026 | EVMN Evommuneoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,673 at $0.00 | filing |
| 2 Jun 2026filed 3 Jun 2026 | EVMN EvommuneBiotechnology | SEC FORM 4 Sold | $110K5,456 at $20.21 | filing |
| 2 Jun 2026filed 3 Jun 2026 | EVMN EvommuneBiotechnology | SEC FORM 4 Sold | $13K600 at $21.38 | filing |
| 7 Nov 2025filed 12 Nov 2025 | EVMN Evommuneoption or derivative · Biotechnology | SEC FORM 4 Code C | —51,588 | filing |
| 7 Nov 2025filed 12 Nov 2025 | EVMN EvommuneBiotechnology | SEC FORM 4 Code C | —6,056 | filing |
| 5 Nov 2025filed 7 Nov 2025 | EVMN Evommuneoption or derivative · Biotechnology | SEC FORM 4 Code A | —37,960 at $0.00 | filing |
| 15 Apr 2023filed 18 Apr 2023 | Timber Pharmaceuticalsoption or derivative | SEC FORM 4 Code A | —4,100 at $0.00 | filing |
| 15 Apr 2023filed 18 Apr 2023 | Timber Pharmaceuticals | SEC FORM 4 Code A | —4,100 at $0.00 | filing |
| 15 Apr 2022filed 19 Apr 2022 | Timber Pharmaceuticalsoption or derivative | SEC FORM 4 Code A | —100,000 at $0.00 | filing |
| 15 Apr 2022filed 19 Apr 2022 | Timber Pharmaceuticals | SEC FORM 4 Code A | —100,000 at $0.00 | filing |
| 9 Nov 2021filed 9 Nov 2021 | Kadmon Holdingsoption or derivative | SEC FORM 4 Code D | $469K64,935 at $7.23 | filing |
| 9 Nov 2021filed 9 Nov 2021 | Kadmon Holdingsoption or derivative | SEC FORM 4 Code D | $721K100,000 at $7.21 | filing |
| 9 Nov 2021filed 9 Nov 2021 | Kadmon Holdingsoption or derivative | SEC FORM 4 Code D | $430K85,034 at $5.06 | filing |
| 9 Nov 2021filed 9 Nov 2021 | Kadmon Holdingsoption or derivative | SEC FORM 4 Code D | $574K96,975 at $5.92 | filing |
| 1 Jul 2021filed 6 Jul 2021 | Timber Pharmaceuticalsoption or derivative | SEC FORM 4 Code A | —71,893 at $0.00 | filing |
| 12 May 2021filed 13 May 2021 | Kadmon Holdingsoption or derivative | SEC FORM 4 Code A | —96,975 at $0.00 | filing |
| 13 May 2020filed 14 May 2020 | Kadmon Holdingsoption or derivative | SEC FORM 4 Code A | —85,034 at $0.00 | filing |
News
Evommune (NYSE:EVMN) Stock Bumped Up to "Hold" by UBS GroupEVMN · tickerreport.com · 14 Oct 2026Evommune (NYSE:EVMN) Upgraded at UBS GroupEVMN · dailypolitical.com · 14 Oct 2026
0 headlines in the last 90 days name David E. Cohen; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.